← Back to Clinical Trials
Recruiting NCT06897553

NCT06897553 ACT for Mental Health in Neurological Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06897553
Status Recruiting
Phase
Sponsor Bielefeld University
Condition Neurological Disorders
Study Type INTERVENTIONAL
Enrollment 44 participants
Start Date 2024-12-01
Primary Completion 2026-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
ACT-based group therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 44 participants in total. It began in 2024-12-01 with a primary completion date of 2026-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to examine the efficacy of this manual for mental health in people with mixed neurological disorders, including post-COVID. These conditions are often associated with cognitive impairment, which may hamper the effects of psychoterapy. Executive functioning and especially the ability to abstract thinking may be useful for individuals using Acceptance and Commitment Therapy. Therefore, the main questions research questions are: * Is this intervention effective in improving mental health? * Do executive functions predict the extent of social participation and mental health at the end of therapy? Participants will take part in 8 weekly group therapy sessions of 100 minutes each.

Eligibility Criteria

Inclusion Criteria: * Value above a cut-off of the DASS-21 subscales (depression \> 10, anxiety \> 6, and stress \> 10) * Sufficient cognition and language ability (clinical rating) * Sufficient therapy motivation (clinical rating) Exclusion Criteria: * Behavioral disorders (e.g., high irritability or apathy in clinical rating) * Other severe mental disorder (dementia, psychosis, personality disorders, intellectual disability) * Simultaneous psychotherapy or neuropsychological therapy

Contact & Investigator

Central Contact

Simon Ladwig, PhD

✉ simon.ladwig@uni-bielefeld.de

📞 +49 (0) 521 106 67533

Principal Investigator

Katja Werheid, Prof

STUDY CHAIR

Bielefeld University

Frequently Asked Questions

Who can join the NCT06897553 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Neurological Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06897553 currently recruiting?

Yes, NCT06897553 is actively recruiting participants. Contact the research team at simon.ladwig@uni-bielefeld.de for enrollment information.

Where is the NCT06897553 trial being conducted?

This trial is being conducted at Bielefeld, Germany.

Who is sponsoring the NCT06897553 clinical trial?

NCT06897553 is sponsored by Bielefeld University. The principal investigator is Katja Werheid, Prof at Bielefeld University. The trial plans to enroll 44 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology